GlassScriptPhysician profile
Khadeeja Ashai
NPI 1831693548
$2,137.42
in general payments reported to CMS, 2019-2025
24 companies · $672 in 2025
The $672 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $377 · 2023: $582 · 2024: $506 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $233.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $197.18 | 2023-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $187.53 | 2023-2025 | Benlysta |
| Ardelyx, INC. | $176.53 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $130.77 | 2022 | |
| Horizon Therapeutics Plc | $123.32 | 2022 | |
| Novo Nordisk INC | $118.67 | 2024-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $116.31 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $106.27 | 2022 | |
| Gilead Sciences, INC. | $86.50 | 2023 | Vemlidy |
| Otsuka America Pharmaceutical, INC. | $86.05 | 2024-2025 | Jynarque |
| Amgen INC. | $63.57 | 2024-2025 | Tavneos |
| Mallinckrodt Hospital Products INC. | $62.81 | 2024-2025 | Terlivaz |
| Vifor Pharma, INC. | $60.21 | 2023-2024 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $59.15 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $58.91 | 2024 | |
| Vantive US Healthcare LLC | $56.25 | 2025 | Renal - Pd |
| Bayer Healthcare Pharmaceuticals INC. | $53.71 | 2025 | |
| Lilly USA, LLC | $49.83 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $29.30 | 2025 | Purified Cortrophin Gel |
| Recor Medical INC | $25.47 | 2025 | Paradise Ultrasound Renal Denervation System |
| Aurinia Pharma U.S., INC. | $23.57 | 2023 | |
| Nxstage Medical, INC. | $17.11 | 2022 | |
| Akebia Therapeutics INC | $14.76 | 2024 | Vafseo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khadeeja Ashai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.